Related Experiment Video
Updated: May 13, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Management of multidrug resistant tuberculosis
Charles L Daley1, Jose A Caminero
1Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206, USA. daleyc@njhealth.org
Seminars in Respiratory and Critical Care Medicine
|March 6, 2013
Summary
Drug-resistant tuberculosis, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, poses a significant global health threat. This review covers the management of these resistant strains, referencing updated World Health Organization guidelines.
Area of Science:
- Microbiology
- Infectious Diseases
- Public Health
Background:
- Drug-resistant Mycobacterium tuberculosis strains are a major global health concern, hindering tuberculosis control efforts.
- Inappropriate treatment has led to the emergence and spread of resistant tuberculosis, particularly in high-risk populations and environments.
- Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are increasingly reported worldwide.
Purpose of the Study:
- To review the current management strategies for MDR-TB and XDR-TB.
- To highlight the updated 2011 World Health Organization (WHO) guidelines for the programmatic management of drug-resistant tuberculosis.
Main Methods:
- Literature review of drug-resistant tuberculosis management.
- Analysis of World Health Organization (WHO) reports and guidelines on tuberculosis treatment.
Main Results:
- An estimated 650,000 cases of MDR-TB occurred in 2010, with significant proportions in new and re-treatment cases globally.
- XDR-TB strains have emerged, showing resistance to additional drug classes.
- A small percentage of MDR-TB cases are currently receiving appropriate therapy with quality-assured drugs.
Conclusions:
- Effective management of MDR-TB and XDR-TB requires adherence to updated programmatic guidelines.
- Addressing the challenges of drug resistance in tuberculosis is critical for global control efforts.
- Improved access to quality-assured drugs and appropriate treatment regimens is essential for combating resistant tuberculosis strains.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: